



Plenary sitting

B8-1403/2016

20.12.2016

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure

on the vaccine against the H1N1 virus

Mireille D'Ornano

Motion for a European Parliament resolution on the vaccine against the H1N1 virus

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
- A. whereas a number of vaccines against the H1N1 virus have been granted EU marketing authorisation, in particular the Pandemrix vaccine ('the vaccine') on 25 May 2008;
- B. whereas a study produced by the VAESCO project in July 2011 has revealed a link between administration of the vaccine and an increased risk of narcolepsy, particularly in subjects below the age of 19;
- C. whereas, moreover, the vaccine is associated with an increased risk of Guillain-Barré syndrome, and whereas the use of squalene-based adjuvants can lead to an increased risk of contracting auto-immune diseases;
- 1. Notes the World Health Organisation's opinions on the vaccine (2009) and that of the European Medicines Agency as updated in May 2016;
- 2. Urges the Commission nonetheless to produce a conclusive study on the links between the vaccine and the aforementioned health risks, drawing in particular on the work of the European Medicines Agency;
- 3. Urges it to amend the recommendations on the vaccine accordingly.